- US-listed companies
- Lyra Therapeutics, Inc.
Lyra Therapeutics, Inc.LYRA
Market cap
$14.77M
P/E ratio
Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | |
Collaboration revenue | - | 0 | 1 |
Research and development | 13 | 30 | 39 |
General and administrative | 10 | 14 | 18 |
Loss on impairment of long-lived assets | - | - | 1 |
Total operating expenses | 22 | 44 | 58 |
Loss from operations | -22 | -44 | -56 |
Interest income | 0 | 0 | 1 |
Total other income | 0 | 0 | 1 |
Loss before income tax expense | - | - | -55 |
Income tax expense | - | - | 0 |
Net loss | -22 | -43 | -55 |
Unrealized holding gain on short-term investments, net of tax | - | - | 0 |
Comprehensive loss | -22 | -44 | -55 |
Net loss per share -basic | - | - | -1.83 |
Net loss per share -diluted | - | - | -1.83 |